Lenalidomide-Dexamethasone as an Effective and Well-Tolerated Treatment Option for Refractory Rosai-Dorfman-Destombes Disease: A Clinical and Pharmacophenomic Study.
Saved in:
| Title: | Lenalidomide-Dexamethasone as an Effective and Well-Tolerated Treatment Option for Refractory Rosai-Dorfman-Destombes Disease: A Clinical and Pharmacophenomic Study. |
|---|---|
| Authors: | Leung E; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health Innovation Hub, Halifax, Nova Scotia, Canada., Fragola NR; Every Cure, Philadelphia, Pennsylvania, USA., Sharp EW; Every Cure, Philadelphia, Pennsylvania, USA., Harrison RA; Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada.; Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada., Peterson E; Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada., Varghese J; Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada., Jackson S; Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada., You XJ; Division of Hematology, McGill University, Montreal, Quebec, Canada., VanderVeer E; Division of Hematology, British Columbia Cancer Agency, Surrey, British Columbia, Canada., Trinder M; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Sutherland A; Division of Dermatology, Dalhousie University, Halifax, Nova Scotia, Canada., Dutz J; Department of Dermatology and Skin Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Kaniewski P; Every Cure, Philadelphia, Pennsylvania, USA., McClain KL; Baylor College of Medicine, Texas Children's Cancer and Hematology Centers, Houston, Texas, USA., Abla O; Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada., Fajgenbaum DC; Every Cure, Philadelphia, Pennsylvania, USA.; Division of Translational Medicine & Human Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Chen LYC; Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health Innovation Hub, Halifax, Nova Scotia, Canada.; Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada.; Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada. |
| Source: | American journal of hematology [Am J Hematol] 2026 Jul; Vol. 101 (7), pp. 1478-1483. Date of Electronic Publication: 2026 Apr 02. |
| Publication Type: | Journal Article; Letter |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
